News archive


‍
‍
‍
‍Press Release Orphan Status EU
‍
‍
Phase 3 Study of 5-ALA in Meningioma Surgery Meets Primary Endpoint
‍
‍Marketing Authorization forGliolan® granted in Jordan
‍
‍SBI Pharma to succeed Marketing Authorization of “Alabel® Oral 1.5g” from Nobelpharma
‍
‍First Patient Enrolled in OVA-302 Study After FDA Orphan Designation for Gleolan®
‍
‍photonamic GmbH & Co. KG successfully obtains Manufacturing License under GMP
‍
‍NX Development Corp. Is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers
‍
‍SBI ALApromo GmbH Announces Registration of 5-aminolevulinic Acid Phosphate Containing Cosmetic, Kiyomi Skin, in Saudi Arabia
‍
‍US FDA Medical Device Registration of Aladuck405/II
‍
‍NutraIngredients-Awardsgranted for clinical study project with the food supplement 5-ALA + SFC as animmune system enhancer for COVID-19 vaccines
‍
‍Photonamic and PhotonicsHealthcare strengthen collaboration after successful clinical pilot study ofoxygen measurement technology
‍
‍Photonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy (“PDT”) in the Field of Non-Small Cell Lung Cancer (NSCLC)
‍
‍FerroSens’ FIDscreen prototype devices successfully applied in clinical study during blood donation
‍
‍First-in-Human Study for New Application of Photodynamic Therapy with 5-Aminolevulinic Acid for Extracorporeal Photopheresis
‍
First Patient Enrolled in Phase 2 Trial with Interstitial Photodynamic Therapy

Breast cancer surgery with 5-ALA, article from Pinneberger Tageblatt
‍
‍Results of Phase II Trial for Breast Cancer Surgery Published in Breast Cancer Research
‍
‍Pinneberg-based pharmaceutical company working on urine test for early cancer detection
‍
‍First Patient Enrolled in Pivotal Phase 3 Trial for Breast Conserving Surgery

Article from Pinneberger Tageblatt, April 2021:
Pinneberg-based pharmaceutical company: Covid drug well tolerated / signs of efficacy.
‍
photonamic Acquires Majority Stake in FerroSens
‍
‍Research with 5-ALA phosphate and Sodium Ferrous Citrate in COVID-19 patients

Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals
‍
Medexus Announces Expanded Availability of Gleolan® in Canada

Case Reports on Treatment with 5-ALA Phosphate for Patients with New Coronavirus Infection (COVID-19)
‍
NX DEVELOPMENT CORP. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan®
‍
NX DEVELOPMENT CORP IN THE USA LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL